Hereditary Angioedema (HAE) Recent News

BioRx is a specialized provider of pharmacy and in-home nursing services for patients with hereditary angioedema (HAE). BioRx is an authorized distributor of BERINERT® (C1 esterase inhibitor, human) and FIRAZYR® (icatibant). BioRx is not a distributor of, nor has access to, CINRYZE™ (C1 esterase Inhibitor, human), manufactured by ViroPharma, Incorporated, or Kalbitor® (ecallantide), manufactured by Dyax Corp. BioRx does not manufacture any pharmaceutical product used in the treatment of HAE, including BERINERT and FIRAZYR. Nothing in this brochure should be construed as medical advice. Patients should consult their physician before starting or changing treatment in any way.

BioRx Expands Therapy Offering to Patients with Hereditary Angioedema

Cincinnati, Ohio (September 12, 2011) —BioRx, a specialty pharmacy company, has received limited distribution rights from Shire Human Genetic Therapies, Inc. (“Shire HGT”) for its new drug, FIRAZYR® (icatibant injection), which received FDA approval on August 25, 2011. As the only FDA-approved self-injectable treatment for hereditary angioedema (HAE), FIRAZYR offers HAE patients an important new option for treating HAE attacks. read more

BioRx Offers Berinert® to Patients with Hereditary Angioedema Deficiency

Cincinnati, Ohio (December 7, 2009) - BioRx, a specialty pharmacy company, has been named one of a small number of approved providers of Berinert®. Berinert® is a plasma-derived concentrate of C1 esterase inhibitor (human) indicated for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) in adult and adolescent patients. CSL Behring, the manufacturer of Berinert P® selected BioRx as part of their distribution network to launch this exciting new product in the United States. read more

C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option

Economic and political factors have led to the increased use of home therapy programmes for patients who have traditionally been treated in hospital. Many patients with hereditary angioedema (HAE) experience intermittent severe attacks that affect their quality of life and may be life-threatening. These attacks are treated with C1-inhibitor concentrate which, for most patients, is infused at the local hospital. Home therapy programmes for HAE are currently being established. This paper reviews the extent of use of these programmes and summarizes the advantages and potential disadvantages of the concept so far. read more